Aubrey Manack Adams

AbbVie

H指数:33

被引数:3,997

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mapping Dural and Periosteal SV2C, a Botulinum Toxin A Receptor, in the Mouse

绘制小鼠硬脑膜和骨膜SV2C（肉毒杆菌毒素A受体）的分布图谱

Toxins 2025, Vol. 17, Page 509

IF0

2025-10-170

OAAI

OnabotulinumtoxinA for the preventive treatment of episodic migraine: Results from the phase 3, multicenter randomized, double-blind, placebo-controlled phase of the PRECLUDE trial

奥纳肉毒毒素A用于发作性偏头痛的预防性治疗：来自PRECLUDE试验第3阶段、多中心、随机、双盲、安慰剂对照阶段的结果

Cephalalgia

IF4.6

2025-10-150

OnabotulinumtoxinA alters pro- and anti-inflammatory dural macrophage response to CSD in female mice

奥纳肉毒杆菌毒素A改变了雌性小鼠中硬脑膜巨噬细胞对CSD的促炎和抗炎反应。

Cephalalgia

IF4.6

2025-09-260

Exploring the effects of extracranial injections of botulinum toxin type A on activation and sensitization of central trigeminovascular neurons by cortical spreading depression in male and female rats

CEPHALALGIA

IF4.6

2024-09-090

PRE

Disability in migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study

CEPHALALGIA

IF4.6

2024-08-231

PRE

Characterizing barriers to care in migraine: multicountry results from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study

JOURNAL OF HEADACHE AND PAIN

IF7.9

2024-08-190

OAAI

Novel insight into atogepant mechanisms of action in migraine prevention

BRAIN

IF11.7

2024-02-274

OAAI

Pre- and post-headache phases of migraine: multi-country results from the CaMEO - International Study

偏头痛的头痛前后阶段: 来自CaMEO国际研究的多国结果

JOURNAL OF HEADACHE AND PAIN

IF7.9

2023-11-088

OAAI

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE

NEUROLOGY AND THERAPY

IF4.8

2023-11-015

OAAI

Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials

HEADACHE

IF4

2023-10-240

OAAI

Multimodal Migraine Management and the Pursuit of Migraine Freedom: A Narrative Review

多模式偏头痛管理与追求无偏头痛状态：叙事性综述

NEUROLOGY AND THERAPY

IF4.8

2023-08-0510

OAAI

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study

JOURNAL OF HEADACHE AND PAIN

IF7.9

2023-08-039

OAAI

Pregnancy Outcomes in Patients Exposed to OnabotulinumtoxinA Treatment A Cumulative 29-Year Safety Update

接受OnabotulinumtoxinA治疗的患者的妊娠结局累积29年安全性更新

NEUROLOGY

IF8.5

2023-07-1112

OAAI

Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) Study: Methods and multi-country baseline findings for diagnosis rates and care

CEPHALALGIA

IF4.6

2023-06-1413

Efficacy of Ubrogepant in the Acute Treatment of Migraine With Mild Pain vs Moderate or Severe Pain

NEUROLOGY

IF8.5

2022-10-2514

OAAI

Atogepant - an orally-administered CGRP antagonist - attenuates activation of meningeal nociceptors by CSD

CEPHALALGIA

IF4.6

2022-03-2517

OnabotulinumtoxinA alters inflammatory gene expression and immune cells in chronic headache patients

BRAIN

IF11.7

2021-12-2124

OAAI

Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials

ADVANCES IN THERAPY

IF4

2021-12-076

OAAI

Medication Overuse and Headache Burden Results From the CaMEO Study

CaMEO研究的药物过度使用和头痛负担结果

NEUROLOGY-CLINICAL PRACTICE

IF3.2

2021-06-0131

OAAI

Barriers to care in episodic and chronic migraine: Results from the Chronic Migraine Epidemiology and Outcomes Study

HEADACHE

IF4

2021-04-0150

OAAI

Aubrey Manack Adams

个人简介

教育背景

工作经历

荣誉奖项

研究方向